Rob Livingston

Rob Livingston is currently the VP, CMC at Priovant. Prior to this, they were the Executive Director, Pharmaceutical Sciences at Repare Therapeutics from December 2021 to March 2022. Rob has also held positions of Senior Director, Pharmaceutical Sciences at Repare Therapeutics from February 2020 to December 2021, Senior Director, Drug Substance Development & Manufacturing at Epizyme from January 2019 to December 2020, Director, Process Development at Radius Health, Inc. from January 2018 to December 2019, and Director, Analytical Development and Director, Chemical Development at Ironwood Pharmaceuticals from January 2014 to December 2018 and from January 2013 to December 2015 respectively. Prior to their positions in management, Rob was a Principal Scientist, Chemical Development at Ironwood Pharmaceuticals from January 2010 to December 2013 and a Senior Research Scientist, Process Research at Gilead Sciences from January 2007 to December 2010. Rob started their career as a Senior Research Investigator, Process Research at Bristol-Myers Squibb from January 2001 to December 2007.

Rob Livingston received their Bachelor of Arts in Chemistry from Williams College. Rob then went on to pursue their Doctor of Philosophy in Organic Chemistry from Stanford University, where they studied under the Barry Trost Group. After completing their PhD, they undertook postdoctoral studies in the Francois Deiderich Group at Eidgenössische Technische Hochschule Zürich.